JP2015501656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501656A5 JP2015501656A5 JP2014547351A JP2014547351A JP2015501656A5 JP 2015501656 A5 JP2015501656 A5 JP 2015501656A5 JP 2014547351 A JP2014547351 A JP 2014547351A JP 2014547351 A JP2014547351 A JP 2014547351A JP 2015501656 A5 JP2015501656 A5 JP 2015501656A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid molecule
- composition
- homologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 81
- 108020004707 nucleic acids Proteins 0.000 claims description 61
- 102000039446 nucleic acids Human genes 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 35
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 12
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 10
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 6
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 11
- 230000000069 prophylactic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569727P | 2011-12-12 | 2011-12-12 | |
| US61/569,727 | 2011-12-12 | ||
| PCT/US2012/069014 WO2013090294A1 (en) | 2011-12-12 | 2012-12-11 | Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072242A Division JP2018102319A (ja) | 2011-12-12 | 2018-04-04 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501656A JP2015501656A (ja) | 2015-01-19 |
| JP2015501656A5 true JP2015501656A5 (cg-RX-API-DMAC7.html) | 2016-01-21 |
| JP6407028B2 JP6407028B2 (ja) | 2018-10-17 |
Family
ID=48613118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547351A Expired - Fee Related JP6407028B2 (ja) | 2011-12-12 | 2012-12-11 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
| JP2018072242A Pending JP2018102319A (ja) | 2011-12-12 | 2018-04-04 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072242A Pending JP2018102319A (ja) | 2011-12-12 | 2018-04-04 | ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9750795B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2791362B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6407028B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140116095A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012352455B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2858884A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013090294A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009158284A2 (en) * | 2008-06-26 | 2009-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| AU2012352455B2 (en) | 2011-12-12 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections |
| AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| SI3019619T1 (sl) | 2013-07-11 | 2021-12-31 | Modernatx, Inc. | Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015196128A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| EP4101930A1 (en) | 2015-09-17 | 2022-12-14 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
| US12385034B2 (en) | 2016-06-24 | 2025-08-12 | Modernatx, Inc. | Methods and apparatus for filtration |
| IL318736A (en) | 2021-06-16 | 2025-03-01 | Conti Innovation Center Llc | Mechanically stacked solar transmissive cells or modules |
| US12414402B1 (en) | 2025-01-03 | 2025-09-09 | Conti Innovation Center, Llc | Optimizing cadmium (CD) alloy solar cells with sputtered copper-dopped zinc telluride (ZNTE:CU) back contacts in the presence of hydrogen |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1006493A (en) | 1911-02-27 | 1911-10-24 | Alwin Mfg Company | Folding perambulator or go-cart. |
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| CH682669A5 (fr) | 1989-03-08 | 1993-10-29 | Health Research Inc | Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants. |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| WO1990011687A1 (en) | 1989-03-31 | 1990-10-18 | Washington University | VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS |
| EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| EP0505151A3 (en) * | 1991-03-19 | 1993-04-07 | Eli Lilly And Company | Preparation of the penicilline binding protein 2a from staphylococcus aureus 27r, purification and use in a resistant-assay |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| CA2153593C (en) | 1993-01-26 | 2010-04-13 | David B. Weiner | Compositions and methods for delivery of genetic material |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6110161A (en) | 1997-04-03 | 2000-08-29 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| BR9810369A (pt) | 1997-06-30 | 2000-09-05 | Rhone Poulenc Rorer Sa | Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação |
| US7060458B1 (en) * | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| WO2000002621A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| EP1233974A4 (en) * | 1999-09-01 | 2004-09-22 | Human Genome Sciences Inc | GENES AND POLYPEPTIDEDES 37 I STAPHYLOCOCCUS AUREUS / I |
| AU2002211524B2 (en) | 2000-10-04 | 2007-03-22 | The Trustees Of The University Of Pennsylvania | Highly expressible genes |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| AU2003295366B2 (en) | 2002-11-04 | 2011-11-24 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| DK2364769T3 (en) | 2003-05-30 | 2016-04-11 | Vgxi Inc | Apparatus and methods for biomaterialeproduktion |
| NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| KR102511874B1 (ko) * | 2006-07-28 | 2023-03-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
| WO2008154101A1 (en) * | 2007-06-06 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus |
| WO2009099716A1 (en) * | 2008-01-11 | 2009-08-13 | Vgx Pharmaceuticals, Inc. | Novel vaccines against multiple subtypes of dengue virus |
| JP2009222712A (ja) * | 2008-02-21 | 2009-10-01 | Univ Nagoya | メチシリン耐性ブドウ球菌の検出法、検出用試薬及び検出用キット |
| WO2009158284A2 (en) * | 2008-06-26 | 2009-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
| KR101667069B1 (ko) | 2008-11-17 | 2016-10-17 | 이노비오 파마수티컬즈, 인크. | 플라비바이러스에 대한 면역반응을 유발하는 항원 및 이를 사용하는 방법 |
| CA2742776A1 (en) | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Releasable cationic lipids for nucleic acids delivery systems |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| AU2012352455B2 (en) | 2011-12-12 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections |
| GB2504774A (en) | 2012-08-10 | 2014-02-12 | Munster Simms Eng Ltd | Diaphragm pump with integral motor housing and rear pump housing |
| TWI548337B (zh) | 2015-10-16 | 2016-09-01 | 技嘉科技股份有限公司 | 散熱模組、顯示卡組件及電子裝置 |
-
2012
- 2012-12-11 AU AU2012352455A patent/AU2012352455B2/en not_active Ceased
- 2012-12-11 EP EP12858266.5A patent/EP2791362B1/en not_active Not-in-force
- 2012-12-11 JP JP2014547351A patent/JP6407028B2/ja not_active Expired - Fee Related
- 2012-12-11 KR KR1020147019093A patent/KR20140116095A/ko not_active Ceased
- 2012-12-11 CA CA2858884A patent/CA2858884A1/en not_active Abandoned
- 2012-12-11 WO PCT/US2012/069014 patent/WO2013090294A1/en not_active Ceased
- 2012-12-11 US US14/365,071 patent/US9750795B2/en active Active
-
2017
- 2017-08-14 US US15/675,823 patent/US10064931B2/en active Active
-
2018
- 2018-04-04 JP JP2018072242A patent/JP2018102319A/ja active Pending
- 2018-08-24 US US16/111,267 patent/US10980870B2/en active Active